MARLO HARGRAVE: Open Payments
NPI 1275041923 · NEWPORT, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,019 in 64 payments from 15 companies in 2025. Trend: 2023 $477 · 2024 $648 · 2025 $1,019
Food & beverage: $1,019
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 14 | $284 |
| ABBVIE INC. | 17 | $184 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $145 |
| E.R. Squibb & Sons, L.L.C. | 2 | $140 |
| Novo Nordisk Inc | 2 | $43 |
| Lundbeck LLC | 2 | $34 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Lilly USA, LLC | 2 | $31 |
| Amgen Inc. | 2 | $29 |
| Abbott Laboratories | 1 | $23 |
Products named: REXULTI, VRAYLAR, CAPLYTA, COBENFY, Ozempic, TRELEGY ELLIPTA, MOUNJARO, FREESTYLE LIBRE 3.
Industry payments across AR — which companies pay providers there.
